Philips Healthcare: Targeting Healthtech Market Recovery Via Value Creation
Challenges Of Recall Add To Pandemic-induced Pressures
Executive Summary
Quality issues relating to a historical acquisition have held back Philips Healthcare’s financial performance in the post-COVID phase, while market competitors have been able to chart a less bumpy path through the tail end of the pandemic. All are facing supply chain and inflationary pressures.
You may also be interested in...
The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge
With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.
FY2022: Medtech Innovators Exchange Top 10 Placings
The leading global medtechs’ fiscal 2022 revenue reports are all in: Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished the year with strong quarters and Roche dropped a few places.
Royal Philips: From Medtech Supplier To Health Care Solutions Partner
Health care delivery has been transformed over the past decade, and so has Royal Philips, whose CEO Frans van Houten explains why both were necessary, and the extra impetus for system-wide change following the COVID-19 pandemic.